0001127602-23-018126.txt : 20230607 0001127602-23-018126.hdr.sgml : 20230607 20230607160539 ACCESSION NUMBER: 0001127602-23-018126 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230605 FILED AS OF DATE: 20230607 DATE AS OF CHANGE: 20230607 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Garay Arpa CENTRAL INDEX KEY: 0001916360 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 23999005 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL RD CITY: KENILWORTH STATE: NJ ZIP: 07033 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 4 1 form4.xml PRIMARY DOCUMENT X0407 4 2023-06-05 0001682852 Moderna, Inc. MRNA 0001916360 Garay Arpa C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 Chief Commercial Officer 1 Common Stock 2023-06-05 4 M 0 4562 A 4837 D Common Stock 2023-06-06 4 S 0 2290 125.7518 D 2547 D Restricted Stock Units 2023-06-05 4 M 0 4562 0 D Common Stock 4562 13686 D Restricted stock units convert into common stock on a one-for-one basis. Includes 275 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on May 31, 2023. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. 25% of the shares subject to this restricted stock unit award vested on June 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. /s/ James Dillon, as Attorney-in-Fact 2023-06-07